Compugen Ltd.

NasdaqCM:CGEN 株式レポート

時価総額:US$126.2m

Compugen マネジメント

マネジメント 基準チェック /34

Compugenの CEO はAnat Cohen-Dayagで、 Jun2009年に任命され、 の在任期間は 15.42年です。 の年間総報酬は$ 1.46Mで、 32.7%給与と67.3%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.063%を直接所有しており、その価値は$ 79.13K 。経営陣と取締役会の平均在任期間はそれぞれ5年と7.4年です。

主要情報

Anat Cohen-Dayag

最高経営責任者

US$1.5m

報酬総額

CEO給与比率32.7%
CEO在任期間15.4yrs
CEOの所有権0.06%
経営陣の平均在職期間5yrs
取締役会の平均在任期間7.4yrs

経営陣の近況

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

CEO報酬分析

Compugen の収益と比較して、Anat Cohen-Dayag の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

US$2m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$479k

-US$19m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$479k

-US$34m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$498k

-US$34m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$453k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$941kUS$395k

-US$27m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$854kUS$391k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$740kUS$392k

-US$37m

報酬と市場: Anatの 総報酬 ($USD 1.46M ) は、 US市場 ($USD 649.07K ) の同規模の企業の平均を上回っています。

報酬と収益: Anatの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Anat Cohen-Dayag (57 yo)

15.4yrs

在職期間

US$1,464,448

報酬

Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Anat Cohen-Dayag
CEO, President & Director15.4yrsUS$1.46m0.063%
$ 79.1k
Eran Ophir
Chief Scientific Officer4.7yrsUS$540.64kデータなし
Zurit Levine
Senior Vice President of Technology Innovation6.8yrsUS$532.26kデータなし
Pierre Ferre
Vice President of Preclinical Development3.6yrsUS$570.40kデータなし
David Silberman
Chief Financial Officerless than a yearデータなしデータなし
Yvonne Naughton
Head of Investor Relations & Corporate Communicationsno dataデータなしデータなし
Eran Dor
General Counsel & Corporate Secretary5.8yrsデータなしデータなし
Dorit Amitay
Vice President of Human Resources17.8yrsデータなしデータなし
Yaron Turpaz
Senior VP & Senior Advisor of Data and Informatics Solutions5yrsデータなしデータなし
Rivka Schwartz
Vice President Research and Discoveryno dataデータなしデータなし
Michelle Mahler
Chief Medical Officerless than a yearデータなしデータなし

5.0yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: CGENの経営陣は経験豊富で経験豊富です(平均在職期間は5年)。


取締役

名称ポジション在職期間報酬所有権
Anat Cohen-Dayag
CEO, President & Director10.8yrsUS$1.46m0.063%
$ 79.1k
Nils Lonberg
Member of Scientific Advisory Board4.2yrsデータなしデータなし
Sanford Zweifach
Independent Director6.4yrsデータなしデータなし
Howard Soule
Member of Scientific Advisory Board11.3yrsデータなしデータなし
Gilead Halevy
Independent Director6.4yrsデータなしデータなし
Paul Sekhri
Independent Chairman of the Board7.1yrsデータなしデータなし
Kinneret Livnat-Savitzky
Independent Director6.4yrsデータなしデータなし
Andrew Pardoll
Chairman of Scientific Advisory Board10.8yrsデータなしデータなし
Antoni Ribas
Member of Scientific Advisory Board11.3yrsデータなしデータなし
Eran Perry
Independent Director5.3yrsデータなしデータなし
Iain McInnes
Member of Scientific Advisory Board11.3yrsデータなしデータなし
Miriam Merad
Member of Scientific Advisory Board7.7yrsデータなしデータなし

7.4yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: CGENの 取締役会経験豊富 であると考えられます ( 7.4年の平均在任期間)。